In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 2.21 a new company low.

Within Major Pharmaceutical Preparations industry 303 other companies have achieved higher Quick Ratio than Trevena Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 1246 to 1487.

Explain Quick Ratio?
How much Cash & cash equivalents TRVN�s has?
What are TRVN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TRVN Quick Ratio	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3
Y / Y Current Liabilities Change	-1.14 %	-36.33 %	-10.13 %	-13.49 %	-33.5 %
Y / Y Cash & cash equivalent Change	-61.48 %	-41.75 %	-14.16 %	-13.95 %	-13.47 %
Quick Ratio MRQ	2.21	3.14	3.27	4.37	5.68
TRVN's Total Ranking	# 1487	# 1246	# 1238	# 1135	# 848
Seq. Current Liabilities Change	16.9 %	-27.76 %	-4.59 %	22.71 %	-24.71 %
Seq. Cash & cash equivalent Change	-17.75 %	-30.51 %	-28.58 %	-5.66 %	24.4 %

Quick Ratio third quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 304
Healthcare Sector	# 530
Overall Market	# 1435

Quick Ratio Statistics
High	Average	Low
33.47	9.69	2.21
(Sep 30 2020)		(Sep 30 2024)

Financial Statements
Trevena Inc 's Current Liabilities	$ 6 Millions	Visit TRVN's Balance sheet
Trevena Inc 's Cash & cash equivalent	$ 13 Millions	Visit TRVN's Balance sheet
Source of TRVN's Sales		Visit TRVN's Sales by Geography

Cumulative Trevena Inc 's Quick Ratio

TRVN's Quick Ratio for the trailling 12 Months

TRVN Quick Ratio	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	-16.18 %	-23.58 %	-18.09 %	-17.9 %	-13.86 %
Y / Y Cash & cash equivalent TTM Growth	-32.96 %	-19.66 %	-23.19 %	-30.21 %	-37.32 %
Quick Ratio TTM	3.31	4.13	4.11	4.13	4.14
Total Ranking TTM	# 3472	# 3140	# 358	# 3263	# 3252
Seq. Current Liabilities TTM Growth	-0.27 %	-10.21 %	-2.72 %	-3.79 %	-9.07 %
Seq. Cash & cash equivalent TTM Growth	-19.93 %	-9.81 %	-3.15 %	-4.15 %	-4.05 %

Quick ratio ranking by company, industry and sector >> Back to TRVN Financial Strength Comparisons >> Go to Compare TRVN Quick Ratio to its Competitors

News about Trevena inc Quick Ratio

Trevena Secures $2M Non-Dilutive Financing Tranche and Exhibits Lower Liabilities, Paving Way for Development Milestones

Trevena Inc., a renowned biopharmaceutical company focused on developing innovative therapies, has recently announced a significant financial milestone as part of its ongoing efforts to advance its lead product, OLINVYK, and achieve commercialization success in the United States. The company expects to receive a non-dilutive $2 million tranche, with the potential for an additional $8 million based on partnering and commercialization milestones for OLINVYK in the US market.
While Trevena Inc. has demonstrated a sequential decrease in its current liabilities during the first quarter of 2024, a closer examination reveals a slight deterioration in its Quick Ratio, falling to 3.27. This is noticeably below the company s average Quick Ratio of 9.63, signaling a potential cause for concern. In fact, 135 other companies within the industry have exhibited higher Quick Ratio figures during the same period.

On the trailing twelve months basis In spite of the year on year decrease in TRVN's Current Liabilities to $6.09 millions, cumulative Quick Ratio to 3.31 below the TRVN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 460 other companies have achieved higher Quick Ratio than Trevena Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3140 to 3472.

Explain Quick Ratio?
How much Cash & cash equivalents TRVN�s has?
What are TRVN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 461
Healthcare Sector	# 936
Within the Market	# 3472

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.81	4.25	1.08
(Sep 30 2020)		(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2024 MRQ Cash & cash equivalent	Sep 30 2024 MRQ Current Liabilities
Ovid Therapeutics Inc	6.08	$ 62.712 Millions	$ 10.317 Millions
Intra cellular Therapies Inc	6.06	$ 1,006.562 Millions	$ 166.113 Millions
Opus Genetics Inc	6.02	$ 36.635 Millions	$ 6.089 Millions
Mira Pharmaceuticals Inc	5.98	$ 4.145 Millions	$ 0.693 Millions
Arrowhead Pharmaceuticals Inc	5.97	$ 578.276 Millions	$ 96.826 Millions
Abeona Therapeutics Inc	5.95	$ 109.701 Millions	$ 18.422 Millions
Minerva Neurosciences Inc	5.92	$ 26.529 Millions	$ 4.483 Millions
Rocket Pharmaceuticals Inc	5.89	$ 235.662 Millions	$ 39.980 Millions
Phio Pharmaceuticals Corp	5.87	$ 5.390 Millions	$ 0.919 Millions
Ataibeckley Inc	5.85	$ 100.920 Millions	$ 17.237 Millions
Allakos Inc	5.80	$ 92.715 Millions	$ 15.981 Millions
Repare Therapeutics Inc	5.77	$ 179.432 Millions	$ 31.084 Millions
Madrigal Pharmaceuticals Inc	5.64	$ 998.627 Millions	$ 176.969 Millions
Vyne Therapeutics Inc	5.60	$ 70.232 Millions	$ 12.538 Millions
Tvardi Therapeutics Inc	5.60	$ 37.061 Millions	$ 6.622 Millions
Inmed Pharmaceuticals Inc	5.56	$ 5.626 Millions	$ 1.012 Millions
Calcimedica Inc	5.45	$ 14.603 Millions	$ 2.679 Millions
Bullfrog Ai Holdings Inc	5.44	$ 4.239 Millions	$ 0.779 Millions
Renovorx Inc	5.40	$ 9.563 Millions	$ 1.772 Millions
Monopar Therapeutics Inc	5.36	$ 6.020 Millions	$ 1.123 Millions
Azitra Inc	5.31	$ 7.260 Millions	$ 1.368 Millions
Phathom Pharmaceuticals Inc	5.13	$ 334.678 Millions	$ 65.288 Millions
Arcus Biosciences Inc	5.07	$ 1,089.000 Millions	$ 215.000 Millions
Spruce Biosciences Inc	5.06	$ 60.055 Millions	$ 11.858 Millions
Io Biotech Inc	4.99	$ 80.185 Millions	$ 16.055 Millions
Igm Biosciences Inc	4.98	$ 218.787 Millions	$ 43.964 Millions
Foghorn Therapeutics Inc	4.71	$ 267.397 Millions	$ 56.824 Millions
Chemomab Therapeutics Ltd	4.60	$ 14.266 Millions	$ 3.103 Millions
Alx Oncology Holdings Inc	4.59	$ 148.574 Millions	$ 32.340 Millions
Sol gel Technologies Ltd	4.53	$ 23.926 Millions	$ 5.285 Millions

Date modified: 2026-09-08T15:11:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.